Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings

Core Insights - Soleno Therapeutics Inc. (NASDAQ: SLNO) experienced a significant decline of 26.59% in stock price, closing at $46.87, marking the fifth consecutive day of losses as investors anticipated strong earnings for Q3 [1][3] - The company reported a net income of $26 million for the third quarter, a 134% improvement from a net loss of $76.6 million in the same period last year, with revenues reaching $66 million [2][3] Company Performance - The strong Q3 results are attributed to increased awareness of the efficacy and safety of Vykat XR, the first and only FDA-approved drug for hyperphagia, particularly within the Prader-Willi Syndrome (PWS) community [3][4] - Vykat XR is positioned as a critical treatment option for patients aged 4 years and older suffering from hyperphagia, addressing a complex patient population with serious co-morbidities [4]